female infertility
Conditions
Interventions
Estradiol supplementation group:17ß-estradiol supplementation vaginally +Crinone supplementation vaginally+ Duphaston p.o.
progesterone:Crinone supplementation vaginally+ Duphaston p.o.
Sponsors
Women’s Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
Female
Age
20 Years to 39 Years
Inclusion criteria
Inclusion criteria: 1. Women undergoing IVF or ICSI using the GnRH antagonist protocol with hMG or FSH for controlled ovarian hyperstimulation; 2. Patients aged 20 to 39 years; 3. Patients on a first or second IVF/ICSI cycle, a body mass index <28 kg/m2, regular menstrual cycles every 24 to 35 days; 4. An informed consent was obtained from all couples who enrolled in the study.
Exclusion criteria
Exclusion criteria: 1.The couple has IVF/ICSI contraindication; 2.Patients with diminished ovarian reserve ( basal FSH >12 IU/mL, and basal total antral follicle count <3); 3.Patients who are scheduled for preimplantation genetic testing; 4.Severe male factor (requiring testicular sperm extraction); 5.Failure of oocytes retrieval; 6.Failed fertilization or no embryo available for transfer; 7.Polycystic ovary syndrome or severe endometriosis (stage III or IV); 8.Patients with hydrosalpinges; 9.An hCG day progesterone level above 1.5ng/ml or endometrial thickness <8mm; 10.An hCG day E2 level above 20000nmol/L (because of ovarian hyperstimulation syndrome risk).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ongoing pregnancy; | — |
Countries
China
Contacts
Public ContactHangying Lou
Women’s Hospital, Zhejiang University School of Medicine, 1 Xueshi Road, Hangzhou, China
Outcome results
None listed